Changshan Pharmaceutical stock volatile amid drug approval uncertainty

Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) has issued an announcement regarding abnormal stock trading fluctuations after consecutive days of significant price increases. The company's statement emphasizes the uncertainty surrounding its Ebendapeptide injection, a drug candidate for type 2 diabetes and weight loss, which is currently under review by the National Medical Products Administration. The announcement clarifies that market competition will be strong if approved, and profitability is not guaranteed. The company also reports a 26.92% YoY decrease in 2024 revenue, posting CNY 103,081.05 million, and a net loss attributable to shareholders of CNY -24,947.77 million. Investors are urged to exercise caution and consider the risks associated with the stock's volatility. The company states its stock has had an increase of 30% over the last 2 trading days, exceeding both industry norms and those of the Shenzhen Composite Index.